{"id":810,"date":"2026-10-20T03:32:17","date_gmt":"2026-10-20T01:32:17","guid":{"rendered":"http:\/\/novameds.local\/de\/?post_type=product&#038;p=810"},"modified":"2026-10-20T04:00:30","modified_gmt":"2026-10-20T02:00:30","slug":"catalog-slu-pp-332-100mg-capsule-60-capsules","status":"publish","type":"product","link":"https:\/\/novameds.health\/de\/produkt\/catalog-slu-pp-332-100mg-capsule-60-capsules\/","title":{"rendered":"SLU-PP-332 (100mg\/capsule), 60 Capsules"},"content":{"rendered":"<section id=\"composition\" data-nav=\"Zusammensetzung und Produktdetails\">\n<h2>Zusammensetzung und Produktdetails<\/h2>\n<div class=\"nm-catalog-document\">\n<div>\n<h2>\u00dcbersicht<\/h2>\n<div>\n<p>SLU-PP-332 is a selective pan-estrogen receptor-related receptor (ERR) agonist with demonstrated activity across ERR\u03b1, ERR\u03b2, and ERR\u03b3 subtypes. The compound exhibits properties related to enhanced mitochondrial biogenesis and oxidative phosphorylation in cellular models. Each unit contains 100mg of the active molecule, supplied in 60-count containers for research applications.<\/p>\n<p>The compound is intended exclusively for analytical and laboratory research purposes.<\/p>\n<ul>\n<li> <span><b>High Purity<\/b> \u2013 99% Purity Guaranteed<\/span><\/li>\n<li> Independently Lab Tested<\/li>\n<li> Research Grade Quality<\/li>\n<li> For Laboratory Research Use Only<\/li>\n<\/ul><\/div>\n<div>\n<p><a href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/5338394\" target=\"_blank\" rel=\"noopener noreferrer\">Molekulardaten bei PubChem<\/a><\/p>\n<\/p><\/div>\n<\/p><\/div>\n<div>\n<h2>Eigenschaften<\/h2>\n<div class=\"nm-catalog-table\" tabindex=\"0\" role=\"region\" aria-label=\"Product data\">\n<table>\n<tbody>\n<tr>\n<th>Chemical Formula<\/th>\n<td>C18H14N2O2<\/td>\n<\/tr>\n<tr>\n<th>Synonyms<\/th>\n<td>4-Hydroxy-N\u2019-(naphthalen-2-ylmethylene)benzohydrazide<\/td>\n<\/tr>\n<tr>\n<th>Molar Mass<\/th>\n<td>290.32 g\/mol<\/td>\n<\/tr>\n<tr>\n<th>CAS Number<\/th>\n<td>303760-60-3<\/td>\n<\/tr>\n<tr>\n<th>PubChem CID<\/th>\n<td>5338394<\/td>\n<\/tr>\n<tr>\n<th>Total Compound Content<\/th>\n<td>6,000 mg (100 mg per capsule)<\/td>\n<\/tr>\n<tr>\n<th>Shelf Life<\/th>\n<td>36 months<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div><\/div>\n<div>\n<h2>Forschung<\/h2>\n<p>\t\t\t\t\t<span>SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptor (ERR) subfamily, exhibiting activity across ERR\u03b1, ERR\u03b2, and ERR\u03b3 receptor subtypes. These orphan nuclear receptors function as constitutively active transcription factors that regulate gene expression programs through interactions with coactivator proteins and transcriptional regulatory complexes. SLU-PP-332 has been characterized as a highly selective and potent pan-ERR agonist, making it a valuable research tool for investigating ERR receptor pharmacology, receptor-coactivator interactions, and nuclear receptor-mediated signaling pathways.<\/span>\t\t\t\t\t<\/div>\n<div>\n<h2>Laborergebnisse<\/h2>\n<p>Results refer to the tested sample. Check the batch and date in the report.<\/p>\n<div>\n<div>\n<div><\/div>\n<div>\n<div>HPLC &#8211; SLU-PP-332 (3583)<\/div>\n<div>September 24, 2026<\/div>\n<\/p><\/div>\n<div><a href=\"https:\/\/swisschems.is\/wp-content\/uploads\/2026\/06\/SC-SLU-PP-332-3583.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Open PDF<\/a><span> \u00b7 <\/span><a href=\"https:\/\/coas.freedomdiagnosticstesting.com\/Swis2609239106.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Laboratory source<\/a><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<div>\n<h2>FAQ<\/h2>\n<div>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>What are estrogen-related receptors (ERRs) and why is SLU-PP-332 significant as a pan-agonist?<\/span><\/p>\n<\/summary>\n<div>\n<p>ERR\u03b1, ERR\u03b2, and ERR\u03b3 are orphan nuclear receptors that function as constitutively active transcription factors within the nuclear receptor superfamily. These receptors regulate gene expression through interactions with coactivator proteins and transcriptional regulatory complexes.<\/p>\n<p>SLU-PP-332 is notable for exhibiting activity across all three ERR subtypes, making it a valuable research tool for investigating pan-ERR receptor pharmacology, receptor-coactivator interactions, and the coordinated regulation of ERR-dependent transcriptional signaling networks.<\/p>\n<\/div>\n<\/details>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>What makes SLU-PP-332 useful for ERR receptor research?<\/span><\/p>\n<\/summary>\n<div>\n<p>SLU-PP-332 possesses a highly selective pan-ERR activity profile, enabling experimental investigation of ERR\u03b1-, ERR\u03b2-, and ERR\u03b3-mediated signaling within a single molecular framework. This characteristic allows researchers to examine receptor activation mechanisms, coactivator recruitment processes, transcriptional control systems, and downstream regulatory pathways associated with ERR signaling.<\/p>\n<p>Its well-characterized pharmacological profile has established it as an important tool for studies of orphan nuclear receptor biology.<\/p>\n<\/div>\n<\/details>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>How does SLU-PP-332 differ from other nuclear receptor agonists?<\/span><\/p>\n<\/summary>\n<div>\n<p>SLU-PP-332 selectively targets the estrogen-related receptor family, whereas many other nuclear receptor agonists act through distinct receptor systems with different signaling architectures and transcriptional regulatory mechanisms. This receptor specificity makes SLU-PP-332 useful for comparative investigations of nuclear receptor pharmacology, receptor-ligand interactions, coactivator biology, and the molecular processes governing receptor-mediated transcriptional regulation.<\/p>\n<\/div>\n<\/details><\/div>\n<\/p><\/div>\n<div>\n<p>Die Hilfsstoffe der Kapsel sind in den verf\u00fcgbaren Produktunterlagen nicht angegeben.<\/p>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>SLU-PP-332 is a selective pan-estrogen receptor-related receptor (ERR) agonist with demonstrated activity across ERR\u03b1, ERR\u03b2, and ERR\u03b3 subtypes.<\/p>\n<p>Darreichungsform: SLU-PP-332 (100mg\/capsule), 60 Capsules.<\/p>\n<p class=\"nm-research-disclaimer\">Nur f\u00fcr die Laborforschung. Nicht zur Anwendung bei Menschen oder Tieren.<\/p>\n<p class=\"nm-catalog-image-note\"><small>Mit KI erstellte illustrative Verpackung.<\/small><\/p>\n","protected":false},"featured_media":973,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[23],"product_tag":[],"nm_classification":[],"class_list":["post-810","product","type-product","status-publish","has-post-thumbnail","product_cat-weight-management-metabolism","first","instock","shipping-taxable","purchasable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/product\/810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/comments?post=810"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/media\/973"}],"wp:attachment":[{"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/media?parent=810"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/product_brand?post=810"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/product_cat?post=810"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/product_tag?post=810"},{"taxonomy":"nm_classification","embeddable":true,"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/nm_classification?post=810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}